| Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo X Ding, AC Sharko, MSJ McDermott, GP Schools, A Chumanevich, H Ji, ... Proceedings of the National Academy of Sciences 119 (32), e2201073119, 2022 | 24 | 2022 |
| CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins M Chen, J Li, L Zhang, L Wang, C Cheng, H Ji, S Altilia, X Ding, G Cai, ... Nucleic Acids Research 51 (14), 7288-7313, 2023 | 18 | 2023 |
| Mediator kinase inhibition reverses castration resistance of advanced prostate cancer J Li, TA Hilimire, Y Liu, L Wang, J Liang, B Gyorffy, V Sikirzhytski, H Ji, ... The Journal of Clinical Investigation 134 (10), 2024 | 5 | 2024 |
| CDK19 and CDK8 Mediator kinases drive androgen-independent in vivo growth of castration-resistant prostate cancer J Li, TA Hilimire, Y Liu, L Wang, J Liang, B Gyorffy, V Sikirzhytski, H Ji, ... Biorxiv, 2023.08. 08.552491, 2023 | 2 | 2023 |
| Abstract P4-01-17: preventing adaptive therapeutic resistance to CDK4/6 inhibition with CDK8/19 inhibitors Z Mack, M Yastrebova, A Khamidullina, A Sharko, X Ding, S Bowe, ... Cancer Research 82 (4_Supplement), P4-01-17-P4-01-17, 2022 | 1 | 2022 |
| CDK8/19 INHIBITORS FOR PREVENTING DRUG RESISTANCE EV Broude, IB Roninson, X Ding, T Hilimire, Z Mack US Patent App. 18/693,105, 2024 | | 2024 |
| Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors X Ding, J Liang, AC Sharko, TA Hilimire, J Li, J Loskutov, ZT Mack, H Ji, ... Proceedings of the National Academy of Sciences 121 (47), e2414501121, 2024 | | 2024 |
| RASSF1 Is identified by transcriptome coordination analysis as a target of ATF4 (Feb, 10.1002/2211-5463.13569, 2023) Y Zhang, KT Huynh-Dam, X Ding, V Sikirzhytski, CU Lim, E Broude, ... FEBS OPEN BIO, 2024 | | 2024 |
| Abstract A043: CDK8/19-regulated transcriptional reprogramming: a druggable driver of castration-resistant prostate cancer J Li, T Hilimire, Y Liu, L Wang, J Liang, B Gyorffy, V Sikitzhytski, H Ji, ... Molecular Cancer Therapeutics 22 (12_Supplement), A043-A043, 2023 | | 2023 |
| RASSF1 is identified by transcriptome coordination analysis as a target of ATF4 Y Zhang, KT Huynh‐Dam, X Ding, V Sikirzhytski, C Lim, E Broude, ... FEBS Open bio 13 (3), 556-569, 2023 | | 2023 |
| Abstract PD5-10: PD5-10 Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer X Ding, H Ji, AC Sharko, J Loskutov, Z Mack, J Myers, M Chen, ... Cancer Research 83 (5_Supplement), PD5-10-PD5-10, 2023 | | 2023 |
| Abstract LB132: CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+ breast cancer via STAT1 and STAT3 X Ding, AC Sharko, MSJ McDermott, H Ji, A Chumanevich, GP Schools, ... Cancer Research 81 (13_Supplement), LB132-LB132, 2021 | | 2021 |
| Transcriptomic and Proteomic Effects of CDK8 and CDK19 Mediator Kinases M Chen, J Li, L Wang, L Zhang, C Cheng, H Ji, S Altilia, X Ding, G Cai, ... | | |
